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Linezolid, a new synthetic antimicrobial, is an important
weapon against methicillin-resistant Staphylococcus aureus
(MRSA). Although there are reports of serotonin syndrome
developing after concomitant use of linezolid and the selec-
tive serotonin reuptake inhibitor paroxitene, this report con-
cerns a patient receiving citalopram who developed throm-
bocytopenia, serotonin syndrome, and lactic acidosis and
died following long-term linezolid therapy.
Linezolid (Pharmacia & Upjohn), a new synthetic antimicro-
bial, is an important weapon against methicillin-resistantStaph-
ylococcus aureus (MRSA). This report concerns a patient who
developed thrombocytopenia, serotonin syndrome, and lactic
acidosis and died following linezolid therapy.
An 81-year-old man, afebrile and of normal mental status,
underwent surgical debridement of ankle osteomyelitis due to
MRSA. He had been receiving citalopram, 20 mg b.i.d., for 3
weeks prior to admission to the hospital. His other medications
included low doses of prednisone and methotrexate, digoxin,
trinitras transdermic patch, torasemid, insulin, and oxazepam.
Following surgery the patient began linezolid therapy at a dos-
age of 600 mg b.i.d. The evolution of the infection was good,
but after 1 week of linezolid therapy changes in the patient’s
mental status became apparent, and at week 3 the patient de-
veloped fever, high blood pressure, tachycardia, confusion, and
tremors without localizable neurologic signs. Blood study re-
sults were as follows: alanine amino transferase, 66 U/L; total
creatine phosphokinase, 766 U/L (mixed blood, 2.2%; platelet
count, 96  109 cells/L; serum lactate level, 17.5 mM; and total
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CO2 concentration, 9 mM. The findings of a CT scan of the
brain were normal. During needle introduction for lumbar
puncture the patient experienced a cardiac arrest. Following
rapid intubation and ventilation, resuscitation without drugs
was successful. The patient’s serum lactate level rose to 29.1
mM, and, in addition to severe lactic acidosis (pH, 6.9), the
hepatic failure worsened. Cardiac ultrasonography showed ma-
jor ventricular dysfunction. The patient died following 3 ad-
ditional cardiac arrest episodes. An autopsy revealed drug en-
cephalopathy and myocardial infarction; the latter probably
occurred after cardiac arrest since the patient’s cardiac isoen-
zyme and troponim levels were normal prior to the arrest. The
results of bacterial cultures were negative, and no other ab-
normalities were noted.
An increasing number of reports have documented adverse
reactions to linezolid, including thromocytopenia [1–4] and
liver toxicity [4]. Serotonin syndrome (fever, agitation with
mental status changes, and tremors [5]) has been noted in 2
recent reports of concomitant use of the selective serotonin
reuptake inhibitor (SSRI) paroxitene and oxazolidinone ther-
apy [6, 7].
Linezolid therapy may not be a long-term treatment option
for a number of patients, particularly elderly patients. If no
other choice is available and linezolid must be administered to
a patient receiving an SSRI, such as citalopram, treatment with
the SSRI should be discontinued at least 2 weeks prior to start-
ing linezolid therapy. In addition, one must be aware of the
risks of lactic acidosis and serious liver damage, and close mon-
itoring of the patient’s blood count, hepatic function, and lac-
tate level is mandatory.
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